Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 16/20 | 1.00 |
| ▸ | CDK2 | P24941 | 13/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 8/20 | 1.00 |
| ▸ | CCNH | P51946 | 8/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 7/20 | 1.00 |
| ▸ | CDK1 | P06493 | 7/20 | 1.00 |
| ▸ | CDK9 | P50750 | 7/20 | 1.00 |
| ▸ | CDK4 | P11802 | 4/20 | 1.00 |
| ▸ | CDK6 | Q00534 | 4/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 4/20 | 1.00 |
| ▸ | CDK8 | P49336 | 3/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.56 |
| ▸ | CCND1 | P24385 | 2/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.56 |
| ▸ | INSRR | P14616 | 1/20 | 0.56 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ct-7001 SCHEMBL31249484 | 1.00 | CDK7 (1.00) | CDK7CDK2CCNE1CCNHMNAT1 | |
| Ct-7001 SCHEMBL20016238 | 1.00 | CDK7 (1.00) | CDK7CDK2CCNE1CCNHMNAT1 | |
| Ct-7001 SCHEMBL20848165 | 1.00 | CDK7 (1.00) | CDK7CDK2CCNE1CCNHMNAT1 | |
| Ct-7001 SCHEMBL18298190 | 0.99 | CDK7 (0.98) | CDK7CDK2CCNE1CCNHMNAT1 | |
| SCHEMBL24791459 | 0.95 | CDK7 (0.91) | CDK7CDK2CCNE1CCNHMNAT1 | |
| SCHEMBL17032283 | 0.93 | CDK7 (0.88) | CDK7CDK2CCNE1CCNHMNAT1 | |
| Hydrochloric Acid SCHEMBL18298199 | 0.93 | CDK7 (0.86) | CDK7CDK2CCNE1CCNHMNAT1 | |
| SCHEMBL24964842 | 0.92 | CDK7 (0.85) | CDK7CDK2CCNE1CCNHMNAT1 | |
| SCHEMBL30209065 | 0.92 | CDK7 (0.85) | CDK7CDK2CCNE1CCNHMNAT1 | |
| SCHEMBL24964839 | 0.92 | CDK7 (0.85) | CDK7CDK2CCNE1CCNHMNAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 414 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029165-A | SAMURACICLIB solid state forms | 阿西亚化学工业有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4695235-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | Cyrus Therapeutics Inc. (KR) | 2026-02-18 | — | — | EP | claimed |
| US-20250367222-A1 | TREATMENTS FOR CANCERS DRIVEN BY DNAJB1-PRKACA GENE FUSIONS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-12-04 | — | — | US | claimed |
| US-20250221989-A1 | PHARMACEUTICAL COMPOSITION, USE THEREOF, AND METHOD FOR TREATING CANCER | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2025-07-10 | — | — | US | claimed |
| EP-4066823-B1 | REDUCED CALORIC INTAKE AND ANTICANCER AGENTS FOR THE TREATMENT OF CANCER | IFOM ST FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS (IT) | 2025-04-30 | — | — | EP | claimed |
| EP-4529926-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | Ascentawits Pharmaceuticals, Ltd. (CN) | 2025-04-02 | — | — | EP | claimed |
| WO-2025057087-A1 | SOLID STATE FORMS OF SAMURACICLIB | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2025-03-20 | — | — | WO | claimed |
| WO-2025051337-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING ORAL CANCER | Afyx Development A/S (DK) | 2025-03-13 | — | — | WO | claimed |
| EP-4506004-A1 | PHARMACEUTICAL COMPOSITION, USE THEREOF, AND METHOD FOR TREATING CANCER | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2025-02-12 | — | — | EP | claimed |
| WO-2025006569-A1 | COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CDK7 INHIBITORS FOR THE TREATMENT OF CANCER | ARVINAS OPERATIONS, INC. (US) | 2025-01-02 | — | — | WO | claimed |
| WO-2024215130-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | CYRUS THERAPEUTICS INC. (KR) | 2024-10-17 | — | — | WO | claimed |
| WO-2023226959-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | 深圳艾欣达伟医药科技有限公司 | 2023-11-30 | — | — | WO | claimed |
| WO-2023186075-A1 | PHARMACEUTICAL COMPOSITION, USE THEREOF, AND METHOD FOR TREATING CANCER | 劲方医药科技(上海)有限公司 | 2023-10-05 | — | — | WO | claimed |
| US-20230210852-A1 | METHODS OF TREATING CANCER IN PATIENTS WITH AN ANOMALOUS KRAS GENE OR DELETIONS WITHIN CHROMOSOME 9 | MEDIC LIFE SCIENCES, INC. | 2023-07-06 | — | — | US | claimed |
| CN-116327956-A | Pharmaceutical composition, use thereof and method for treating cancer | 劲方医药科技(上海)有限公司 | 2023-06-27 | — | — | CN | claimed |
| US-20230146795-A1 | ENHANCEMENT OF ANTI-TUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NOVEL CANCER MEDICINES IN CANCERS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | claimed |
| EP-4157465-A2 | METHODS OF TREATING CANCER IN PATIENTS WITH AN ANOMALOUS KRAS GENE OR DELETIONS WITHIN CHROMOSOME 9 | Syros Pharmaceuticals, Inc. (US) | 2023-04-05 | — | — | EP | claimed |
| US-20220313694-A1 | REDUCED CALORIC INTAKE AND ANTICANCER AGENTS FOR THE TREATMENT OF CANCER | IFOM FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2022-10-06 | — | — | US | claimed |
| EP-4066823-A1 | REDUCED CALORIC INTAKE AND ANTICANCER AGENTS FOR THE TREATMENT OF CANCER | IFOM Fondazione Istituto Firc di Oncologia Molecolare (IT) | 2022-10-05 | — | — | EP | claimed |
| US-20220288067-A1 | TREATMENT OF CANCER WITH CDK INHIBITORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-09-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221989-A1 | PHARMACEUTICAL COMPOSITION, USE THEREOF, AND METHOD FOR TREATING CANCER | KRAS, NRAS, HRAS | CDK7 133/4885CDK2 134/4885CCNE1 332/4885 |
| US-20230210852-A1 | METHODS OF TREATING CANCER IN PATIENTS WITH AN ANOMALOUS KRAS GENE OR DELETIONS WITHIN CHROMOSOME 9 | CDKL5, KRAS, CDK9 | CDK7 12/4885CDK2 28/4885CCNE1 134/4885 |
| US-20230146795-A1 | ENHANCEMENT OF ANTI-TUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NOVEL CANCER MEDICINES IN CANCERS | PTPN5, PTPN7, PTPN1 | CDK7 480/4885CDK2 558/4885CCNE1 2173/4885 |
| US-20220288067-A1 | TREATMENT OF CANCER WITH CDK INHIBITORS | CDK3, CDK4, CDK1 | CDK7 18/4885CDK2 6/4885CCNE1 39/4885 |
| US-20250367222-A1 | TREATMENTS FOR CANCERS DRIVEN BY DNAJB1-PRKACA GENE FUSIONS | CDK9, CDC73, CDK4 | CDK7 10/4885CDK2 122/4885CCNE1 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.